CellRep Bio

Startup Plus

CellRep transforms CAR-T manufacturing with AI-discovered small molecules that reprogram T cells into more potent, persistent therapeutic agents. Our lead compound demonstrates 6.6x improvement in polyfunctionality (52.8% vs 8% baseline) with simultaneous reduction in exhaustion markers—addressing the fundamental challenge limiting CAR-T efficacy in solid tumors.

Key advantage: Our compounds function as manufacturing reagents rather than drugs, enabling integration into existing CAR-T production without separate IND approval. This regulatory pathway accelerates clinical translation significantly.

Currently advancing through preclinical validation at Baylor College of Medicine. First-in-human trials targeted Q3-Q5 2026.

website